Spondylarthropathies: Clinical Trials

120 trials for Spondylarthropathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

64 completed, 19 unknown, 13 recruiting, 7 withdrawn. 120 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 4120Completed 64, Unknown 19, Recruiting 13, Withdrawn 7, Not yet recruiting 6, Terminated 6, Active not recruiting 4, Enrolling by invitation 1

Follow Spondylarthropathies: new trials by email Literature Review of Spondylarthropathies trials Research Report on Spondylarthropathies

Trials (filtered) newest first · largest first

All 120 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
Secukinumab (IL-17i ), Upadacitinib (JAKi) - Axial Spondyloarthritis (AxSpA)
Phase 4Not yet recruitingThe University of Texas Health Science Center, Houston402026-11-012026-10-14
Ivarmacitinib With or Without Celecoxib for Ankylosing Spondylitis
Ivarmacitinib with celecoxib, Ivarmacitinib Monotherapy - Ankylosing Spondylitis (AS)
Phase 4Not yet recruitingPeking University Third Hospital1382026-10-252026-10-27
A Clinical Trial of Antiplatelets in Psoriasis
Aspirin, Clopidogrel, Placebo - Psoriasis (PsO), Psoriatic Arthritis (PsA)
Phase 4Not yet recruitingNYU Langone Health602026-09-012026-08-05
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
Breast Milk Sample Collection, Guselkumab - Psoriasis, Colitis, Ulcerative
Phase 4RecruitingJanssen Research & Development, LLC102026-08-072026-11-03
Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease
Deucravacitinib, Placebo - Psoriatic Arthritis (PsA)
Phase 4RecruitingUniversity of Texas Southwestern Medical Center1282026-06-162026-09-01
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
Upadacitinib 15 MG [Rinvoq] - Axial Spondylarthritis (axSpA)
Phase 4Not yet recruitingCARE ARTHRITIS LTD.2002026-05-012026-02-06
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
GLP-1 agonists, Nutrition Counseling - Psoriatic Arthritis (PsA)
Phase 4RecruitingMedical College of Wisconsin222026-05-012026-11-05
Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)
Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Phase 4RecruitingInstituto de Investigación Marqués de Valdecilla11172026-04-222026-11-19
Effectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study
Acemetacin - Axial Spondyloarthritis, Axial Spondyloarthritis, Non-Radiographic
Phase 4Not yet recruitingChinese PLA General Hospital1502026-04-012026-05-12
Preventing Structural Damage in Early Psoriatic Arthritis
Amgevita 40Mg Solution for Injection, Methotrexate (Metoject® prefilled pen) - Psoriatic Arthritis (PsA)
Phase 4RecruitingChinese University of Hong Kong1082026-03-162026-03-23
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Dengue 1,2,3,4 (attenuated) vaccine - Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Phase 4RecruitingUniversity of Sao Paulo General Hospital4772026-03-162026-07-20
REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases
JAKi dose reduction strategy, JAKi disease activity guided continuation of same dose strategy - Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Phase 4RecruitingSint Maartenskliniek2002025-09-152025-09-17
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Guselkumab - Arthritis, Psoriatic
Phase 4RecruitingJohnson & Johnson Private Limited1002025-08-122026-08-28
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
Prescreen platform, biologics treatment - Psoriasis, Psoriasis Arthritis
Phase 4RecruitingTaichung Veterans General Hospital502025-07-292025-09-02
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
Etanercept, Benzathine Penicillin, Placebo - Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)
Phase 4RecruitingNanfang Hospital, Southern Medical University3402025-06-142025-06-26
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
Tirzepatide - Psoriatic Arthritis, Overweight or Obesity
Phase 4Active not recruitingEli Lilly and Company2002025-03-062026-09-21
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Secukinumab, Adalimumab - Ankylosing Spondylitis
Phase 4Not yet recruitingThe Affiliated Hospital Of Guizhou Medical University102025-02-012025-02-18
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Shingrix, vaccination with 2 doses of Shingrix vaccine - Systemic Vasculitis, Spondylarthropathies
Phase 4Enrolling by invitationRegion Skane2402024-12-172025-01-10
A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
Upadacitinib 15 MG [Rinvoq], Placebo - Psoriatic Arthritis, Spondyloarthritis, Axial
Phase 4RecruitingCARE ARTHRITIS LTD.1002024-12-032026-04-03
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Secukinumab 300mg s.c., Secukinumab 150mg s.c. - Ankylosing Spondylitis (AS)
Phase 4RecruitingTongji Hospital1002024-06-142026-01-27

Showing 20 of 120. Sign in to see all of them.

Narrower conditions

Spondylitis, Ankylosing (59)  ·  Arthritis, Psoriatic (48)  ·  Axial Spondyloarthritis (18)  ·  Arthritis, Rheumatoid (12)  ·  Psoriasis (10)  ·  Spondylarthritis (10)  ·  Arthritis (4)  ·  Crohn Disease (4)  ·  Arthritis, Juvenile (3)  ·  Lupus Erythematosus, Systemic (3)  ·  Non-Radiographic Axial Spondyloarthritis (3)  ·  Uveitis, Anterior (3)  ·  Colitis, Ulcerative (2)  ·  Herpes Zoster (2)

Broader conditions

Bone Diseases (120)  ·  Musculoskeletal Diseases (120)  ·  Spinal Diseases (120)  ·  Joint Diseases (119)  ·  Spondylitis (118)  ·  Arthritis (116)  ·  Spondylarthritis (110)  ·  Ankylosis (74)  ·  Axial Spondyloarthritis (56)  ·  Skin and Connective Tissue Diseases (53)  ·  Skin Diseases (48)  ·  Skin Diseases, Papulosquamous (48)  ·  Psoriasis (38)  ·  Autoimmune Diseases (13)

Interventions

Etanercept (29)  ·  Adalimumab (19)  ·  Infliximab (16)  ·  secukinumab (13)  ·  Methotrexate (9)  ·  golimumab (8)  ·  Celecoxib (6)  ·  Sulfasalazine (6)  ·  apremilast (5)  ·  Certolizumab Pegol (4)  ·  upadacitinib (4)  ·  Diclofenac (3)  ·  Tumor Necrosis Factor Inhibitors (3)  ·  guselkumab (3)  ·  ixekizumab (3)

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer (9)  ·  Chinese University of Hong Kong (6)  ·  Merck Sharp & Dohme LLC (6)  ·  Sun Yat-sen University (6)  ·  Pfizer (5)  ·  Novartis Pharmaceuticals (4)  ·  Amgen (3)  ·  Charite University, Berlin, Germany (3)  ·  Eli Lilly and Company (3)  ·  Nanfang Hospital, Southern Medical University (3)  ·  AbbVie (2)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (2)  ·  CARE ARTHRITIS LTD. (2)  ·  Chung Shan Medical University (2)  ·  Gu Jieruo (2)

Countries

United States (23)  ·  China (20)  ·  Germany (19)  ·  France (13)  ·  Denmark (12)  ·  Spain (11)  ·  Netherlands (10)  ·  United Kingdom (10)  ·  Canada (9)  ·  Italy (9)  ·  Poland (9)  ·  Sweden (9)  ·  Finland (8)  ·  Hungary (8)  ·  Belgium (7)

Top investigators

Jieruo Gu, Prof (3)  ·  Edmund K Li, MD (2)  ·  Lai Shan Tam, MD (2)  ·  Walter Maksymowych, Dr. (2)  ·  Bogdan Batko, MD, PhD (1)  ·  Charlotte Wiell, MD, PhD (1)

Results publications

PMID 38488976, PMID 19740906, PMID 20124563, PMID 20511606, PMID 21317434, PMID 21341463, PMID 21551511, PMID 21630245, PMID 21639907, PMID 21700683, PMID 21834061, PMID 22006544, PMID 22035157, PMID 22127697, PMID 22337244, PMID 22653382, PMID 22824238, PMID 23286772, PMID 23981683, PMID 24286269, PMID 24369412, PMID 24501241, PMID 24861696, PMID 25428762, PMID 25535650, PMID 25656734, PMID 25913550, PMID 25986458, PMID 26242443, PMID 26568588, PMID 27449221, PMID 28502609, PMID 28601821, PMID 28619118, PMID 28785857, PMID 30323006, PMID 30473179, PMID 30621746, PMID 30762274, PMID 31958280, PMID 32660977, PMID 32965617, PMID 33195311, PMID 33200394, PMID 33854572, PMID 35035537, PMID 35279805, PMID 35393269, PMID 35428722, PMID 36064592

NIH funding

2015 (4), 2016 (4), 2023 (3), 2005 (2), 2017 (2), 2018 (2), 2009 (1), 2014 (1), 2025 (1), K23HL152013 (1)